// App-Quantinova.ai

1400 : Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Michael E. Rytting

Principal Investigators

  • Deborah A. Thomas

  • Susan -Brien

  • Gautam Borthakur

  • Steven M. Kornblau

  • Hagop M. Kantarjian

  • Kurt Schroeder

  • Rebecca Garris

  • Jorge Cortes

  • Farhad Ravandi

  • Naveen Pemmaraju

  • Naval Daver

  • Stefan H. Faderl

  • Anna R.K. Franklin

Medical Centers

  • Childrens Cancer Hospital at MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, HOUSTON, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Leukemia, MDACC, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hyperbilirubinemia

  • Avascular necrosis

  • Pancreatitis

  • T-cell acute lymphoblastic leukemia

  • Venous thrombosis

  • Lymphomas

Biomarkers

  • Alanine transaminase

  • Breakpoint Cluster Region

  • Ph chromosome

  • White Blood Cell

Drug/Treatment

  • PEG-asparaginase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved